Definition
Avastin® made by Genentech/Roche.
Monoclonal antibody against the vascular endothelial growth factor (VEGF). Bevacizumab has activity in colorectal cancer(Colorectal Cancer Therapeutic Antibodies), non-small-cell lung cancer, breast cancer, and ovarian cancer. Binding to VEGF prevents it from binding to its receptor. Originally approved by the US FDA for the treatment of colorectal cancer.
VEGF stimulates the growth of new blood vessels, a process called angiogenesis. The binding of bevacizumab is designed to inactivate VEGF so that it is no longer an effective stimulant for angiogenesis. As a result, new blood vessels are not formed. Cancers depend on the development of new blood vessels to grow. Without an adequate supply of blood, they cannot get larger and may even shrink. Bevacizumab does not work directly on the tumor, but prevents its growth by reducing its supply of blood. Bevacizumab does not cure cancer, but it can slow down its growth and increase survival times....
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11(12):1172–83
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
(2011). Bevacizumab. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16483-5_595
Download citation
DOI: https://doi.org/10.1007/978-3-642-16483-5_595
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16482-8
Online ISBN: 978-3-642-16483-5
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences